- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05534750
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis (TEDITUB) (TEDITUB)
Evaluation of the Early Bactericidal Activity of Tedizolid and Linezolide Against Mycobacterium Tuberculosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a Phase 2, prospective, randomized, open-label controlled trial in 3 parallel groups comparing tedizolid with 2 standard treatments: linezolid (oxazolidinone whose anti-tuberculosis activity has already been demonstrated) and standard treatment for tuberculosis (quadruple therapy: isoniazid, rifampicin, ethambutol, pyrazinamide ). The objective is to measure the early bactericidal activity of tedizolid, to compare it with the bactericidal activity of linezolid and with that of standard quadruple therapy.
Design: A multicentric, open-label, randomized clinical trial
Sample size : 60 patients, 20 in each group
Treatments groups:
Tedizolid arm:
- Tedizolid (SIVEXTRO®),
- 200 mg film-coated tablet
- Dosage of 1 tablet per day to be taken in the morning for 7 days (taken with or without meals).
Linezolid arm (ZYVOXID®):
- Linezolid arm (ZYVOXID®)
- 600 mg film-coated tablet
- Dosage of 2 tablets per day to be taken in the morning for 7 days (taken with or without meals).
Standard quadruple therapy arm:
- Isoniazid (RIMIFON®) Tablets 50 or 200 mg Dosage 3 to 5mg / kg / day for 7 days to be taken in the morning on an empty stomach.
- Rifampicin, dosage 10mg / kg / day for 7 days to be taken in the morning on an empty stomach.
- Ethambutol 15-20mg / kg / day for 7 days to be taken in the morning on an empty stomach.
- Pyrazinamide 20-25mg / kg / day for 7 days to be taken in the morning on an empty stomach.
Treatment duration : 7 days
Assessement:
After signing the consent, patients will be randomized, a sputum sample will be taken before the first drug intake. Then, patients will be treated for 7 days depending on the randomization group (tedizolid, linezolid or standard quadruple therapy). Daily, a sputum of at least 2 mL will be withdrawn from the patients for 7 days.
A consultation with blood test will be carried out on D30, date of the patient's end of participation.
No interim analysis is planned. Analysis will be performed at the end of the study after data review and freezing of database.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Ruxandra CALIN, MD
- Phone Number: 01 56 01 74 12
- Email: ruxandra.calin@aphp.fr
Study Contact Backup
- Name: Nicolas VEZIRIS, PU-PH
- Phone Number: 01 49 28 30 41
- Email: nicolas.veziris@aphp.fr
Study Locations
-
-
-
Paris, France, 75012
- Recruiting
- Bacteriology department- Hôpital Saint-Antoine
-
Contact:
- Ruxandra CALIN, MD
- Phone Number: 01 56 01 74 12
- Email: ruxandra.calin@aphp.fr
-
Contact:
- Nicolas VEZIRIS, PU-PH
- Phone Number: 01 49 28 30 41
- Email: nicolas.veziris@aphp.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age ≥ 18 years old and <75 years old
- Woman on childbearing age should be on effective contraception during the duration of the study and up to 6 months after treatment; a mechanical contraception (use of condom) will be strongly recommended
- Male (effective contraception must be used during duration of the study and up to 3 months after treatment)
- Patient with a first infection with Mycobacterium tuberculosis of pulmonary localization suspected by the presence of a clinical pulmonary symptomatology, a chest X-ray or an abnormal chest computed tomography, and the positive microscopic examination of a sputum (AFB +, presence of AFB) with confirmation of tuberculosis by a genotypic test demonstrating no resistance to rifampicin, without clinical signs of extra-thoracic involvement
- State medical assistance application being processed ( If patient does not benefit from social security),
- Signature of informed consent
Exclusion Criteria:
- Resistance to one of the anti-tuberculosis drugs used detected by a genotypic test in accordance with the recommendations of the High Council of Public Health of 2015;
- History of anti-tuberculosis treatment;
- History of treatment in the previous two years with one of the antibiotics evaluated in this trial lasting more than one month;
- Absolute contraindication to the use of at least one of the test molecules (isoniazid, rifampicin, ethambutol, pyrazinamide, linezolid, tedizolid);
- Tuberculosis having, in the opinion of the investigator, severity criteria not allowing to wait 7 days before starting standard treatment (oxygenorequirement, severe immunosuppression, extra-pulmonary involvement, any sign of severity requiring treatment in intensive care unit);
- HIV-infected patient receiving protease inhibitors whose antiviral treatment cannot be changed and therefore cannot receive rifampicin; or any other drug contraindicated with one of the study treatments (the list of contraindicated drugs is detailed in the following non-inclusion criteria).
- Neoplastic pathology during treatment with chemo and / or radiotherapy;
- Decompensated cirrhosis;
- Pregnancy, desire to become pregnant, breast-feeding (for women of childbearing potential, contraception should be used for the duration of the study and up to 6 months after treatment, mechanical contraception will be strongly recommended and up to 3 months after treatment);
- Protected adults (under guardianship, curatorship) and under safeguard of justice
- Significant laboratory abnormalities (hemoglobin <9g / dl, polynuclear neutrophils <500 / mm3, platelets <50,000 / mm3, creatinine clearance <30ml / min, ASAT or ALAT> 3N, and total bilirubin> 3N)
- Hyperuricaemia
- Porphyria
- Optic neuritis or peripheral neuropathy
- BMI≤ 16 kg/m2
- Participation in other interventional research
- Current treatment with one or more medications contraindicated in combination with linezolid: Linezolid should not be used in patients treated with monoamine oxidase A or B inhibitors (for example: phenelzine, isocarboxacid, selegiline, moclobemide) or who received one of these products in the previous two weeks
- Current treatment with one or more medications contraindicated in combination with quadritherapy:
- Combination with bictegravir, cobicistat, daclatasvir, dasabuvir, delamanid, grazoprevir/elbasvir, protease inhibitors boosted by ritonavir, isavuconazole, ledipasvir, lurasidone, midostaurin, ombitasvir/paritaprevir, praziquantel, rilpivirine, sofosbuvir, velpatasvir, voriconazole, voxilaprevir
- Gastrointestinal topicals, antacids and adsorbents and salts and aluminum hydroxides
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tedizolid arm
Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days.
Then, the early bactericidal activity will be measured and compared to the other arms.
|
Patients will be taken 1 tablet per day of 200 mg film-coated of Tedizolid (SIVEXTRO®), in the morning for 7 days.
Then, the early bactericidal activity will be measured and compared to the other arms.
|
Experimental: Linezolid arm
Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days.
Then, the early bactericidal activity will be measured and compared to the other arms.
|
Patients will be taken 2 tablets per day of 600 mg film-coated of Linezolid (ZYVOXID®) in the morning for 7 days.
Then, the early bactericidal activity will be measured and compared to the other arms.
|
Active Comparator: Standard quadruple therapy arm
Patients will be taken : ISONIAZIDE : o A dosage of 3 to 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®) RIFAMPICINE : o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach) ETHAMBUTOL : o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol PYRAZAMIDE : o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide Then, the early bactericidal activity will be measured and compared to the other arms. |
Patients will be taken : ISONIAZIDE : o A dosage of 5mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Isoniazid (RIMIFON®) RIFAMPICINE : o A dosage of 10mg / kg / day for 7 days (to be taken in the morning on an empty stomach) ETHAMBUTOL : o A dosage of 15-20mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Ethambutol PYRAZAMIDE : o A dosage of 20-25mg / kg / day for 7 days (to be taken in the morning on an empty stomach) of Pyrazinamide Then, the early bactericidal activity will be measured and compared to the other arms. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of the early bactericidal activity (EBA) of tedizolid (200mg / day) at the end of the first 2 days of treatment (D3).
Time Frame: Day 3
|
The measurement will be done as follow: EABD1D3= (log10 number of CFU (CFU= colony forming unit) of M. tuberculosis on medium 7H11/mL of sputum on D1) - (log10number of CFU of M. tuberculosis on medium 7H11/mL of sputum on D3)/2.
|
Day 3
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Evaluation of the early bactericidal activity (EBA) of tedizolid between Day 3 and Day 8
Time Frame: Day 8
|
The measurement will be done as follow: EBAD3D8= (log10 number of CFU (CFU=colony forming unit) of M. tuberculosis on medium 7H11/mL of sputum on D3) - ( log10 number of CFU of M. tuberculosis on medium 7H11/mL of sputum at D8)/5
|
Day 8
|
Comparison of the early bactericidal activity (EBA) of tedizolid between Day 1 and Day 3
Time Frame: Day 3
|
Compare the early bactericidal activity of tedizolid 200 mg / day to that of linezolid 1200 mg / day between Day 1 and Day 3
|
Day 3
|
Comparison of the early bactericidal activity (EBA) of tedizolid between Day 3 and Day 8
Time Frame: Day 8
|
Compare the early bactericidal activity of tedizolid 200 mg / day to that of linezolid 1200 mg / day between Day 1 and Day 3 and between Day 3 and Day 8
|
Day 8
|
Comparison of the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 1 and Day 3
Time Frame: Day 3
|
Compare the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 1 and Day 3
|
Day 3
|
Comparison of the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 3 and Day 8
Time Frame: Day 8
|
Compare the early bactericidal activity of tedizolid 200 mg / day to that of standard quadruple therapy between Day 3 and Day 8
|
Day 8
|
Tedizolid pharmacokinetics'measurement
Time Frame: 24hours
|
To measure the total and free concentration of tedizolid measured at 0, 1, 3, 5 and 24hours
|
24hours
|
Evaluation of Tedizolid's tolerance on hemoglobin
Time Frame: 30 days
|
Rate of patients with hemoglobin <9, g / dl, which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on polynuclear neutrophils
Time Frame: 30 days
|
Rate of patients with polynuclear neutrophils <500 / mm3, which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on platelets
Time Frame: 30 days
|
Rate of patients with platelets <30,000 / mm3 which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on creatinine clearance
Time Frame: 30 days
|
Rate of patients with creatinine clearance <30ml / min which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on AST/ALT
Time Frame: 30 days
|
Rate of patients with AST or ALT> 5N which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on bilirubin
Time Frame: 30 days
|
Rate of patients with total bilirubin> 5N which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on dress syndrome
Time Frame: 30 days
|
Rate of patients with dress syndrome which will lead to premature discontinuation of the administration of the treatment.
|
30 days
|
Evaluation of Tedizolid's tolerance on optic neuropathy
Time Frame: 30 days
|
Rate of patients with optic neuropathy which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Evaluation of Tedizolid's tolerance on peripheral neuropathy
Time Frame: 30 days
|
Rate of patients with rapidly progressive peripheral neuropathy, which will lead to premature discontinuation of the administration of the treatment
|
30 days
|
Collaborators and Investigators
Investigators
- Principal Investigator: Nicolas VEZIRIS, PU-PH, Assistance Publique - Hôpitaux de Paris
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Gram-Positive Bacterial Infections
- Actinomycetales Infections
- Mycobacterium Infections
- Tuberculosis
- Tuberculosis, Multidrug-Resistant
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Enzyme Inhibitors
- Anti-Bacterial Agents
- Protein Synthesis Inhibitors
- Linezolid
- Tedizolid
- Tedizolid phosphate
Other Study ID Numbers
- APHP210084
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tuberculosis
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
Global Alliance for TB Drug DevelopmentCompletedTuberculosis | Tuberculosis, Pulmonary | Pulmonary Disease | Multi Drug Resistant Tuberculosis | Drug Sensitive Tuberculosis | Drug-resistant Tuberculosis | Mycobacterium Tuberculosis InfectionUnited States
-
University of Cape TownUniversity of Stellenbosch; University of Cape Town Lung Institute; University... and other collaboratorsCompletedTuberculosis | Multidrug Resistant Tuberculosis | Extensively-drug Resistant TuberculosisSouth Africa
-
Universiteit AntwerpenAurum Institute; University of Stellenbosch; University of the Free State; Free...RecruitingDrug-resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses | Multidrug Resistant TuberculosisSouth Africa
-
Assistance Publique - Hôpitaux de ParisCompletedExtrapulmonary Tuberculosis | Lymph Node Tuberculosis | Bone TuberculosisFrance
-
Centers for Disease Control and PreventionBoston University; Pfizer; Columbia University; University of Texas; University of... and other collaboratorsCompletedMulti-Drug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisSouth Africa
-
University Medical Center GroningenCompletedMultidrug-resistant Tuberculosis | Extensively Drug-resistant TuberculosisNetherlands
-
Foundation for Innovative New Diagnostics, SwitzerlandInstitute of Tropical Medicine, Belgium; Research Center Borstel; National Institute...CompletedMultidrug-Resistant Tuberculosis | Isoniazid Resistant Pulmonary Tuberculosis | Rifampicin Resistant Tuberculosis | Pulmonary Tuberculoses
-
National Institute of Allergy and Infectious Diseases...CompletedPulmonary Tuberculosis | Multidrug Resistant Tuberculosis | Extensively Drug Resistant TuberculosisKorea, Republic of
-
Wits Health Consortium (Pty) LtdUniversity of Cape Town; Perinatal HIV Research Unit of the University of the... and other collaboratorsActive, not recruitingTuberculosis | Multi Drug Resistant Tuberculosis | Rifampicin Resistant Tuberculosis | Extensively Drug-Resistant Tuberculosis | Pre-XDR-TBSouth Africa
Clinical Trials on Tedizolid arm (SIVEXTRO®)
-
Amit.PaiMerck Sharp & Dohme LLCCompleted
-
Lundquist Institute for Biomedical Innovation at...CompletedBone and Joint InfectionUnited States
-
Cubist Pharmaceuticals LLCCompleted
-
BayerTerminatedSkin Disease, InfectiousRussian Federation, Mexico, Singapore
-
Merck Sharp & Dohme LLCCompleted
-
BayerCompletedSkin Diseases, InfectiousJapan
-
Hartford HospitalMerck Sharp & Dohme LLCCompletedDiabetes | Healthy Volunteers | Wound InfectionUnited States
-
Fundacion Clinic per a la Recerca BiomédicaUnknown
-
Cubist Pharmaceuticals LLCCompletedSkin Diseases, Infectious | Skin Diseases, Bacterial
-
Hospital Pedro HispanoUnknownBleeding After Resection of Colorectal Neoplastic LesionsPortugal